About Roivant Sciences Ltd.
https://roivant.comRoivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines.
CEO
Matthew Gline
Compensation Summary
(Year 2023)
ETFs Holding This Stock
Summary
Showing Top 3 of 215
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Goldman Sachs
Buy
HC Wainwright & Co.
Buy
Citigroup
Buy
Guggenheim
Buy
Jefferies
Buy
Leerink Partners
Outperform
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
FMR LLC
Shares:60.77M
Value:$1.45B
MORGAN STANLEY
Shares:44.32M
Value:$1.06B
SB INVESTMENT ADVISERS (UK) LTD
Shares:40.32M
Value:$959.9M
Summary
Showing Top 3 of 361
About Roivant Sciences Ltd.
https://roivant.comRoivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $1.57M ▼ | $307.69M ▲ | $-113.52M ▲ | -7.23K% ▲ | $-0.17 ▲ | $-158.12M ▲ |
| Q1-2025 | $2.17M ▼ | $286.94M ▼ | $-223.35M ▼ | -10.29K% ▼ | $-0.33 ▼ | $-283.82M ▼ |
| Q4-2024 | $7.57M ▼ | $292.33M ▲ | $-206.47M ▼ | -2.73K% ▼ | $-0.29 ▼ | $-283.54M ▼ |
| Q3-2024 | $9.02M ▲ | $283.14M ▼ | $169.38M ▲ | 1.88K% ▲ | $0.23 ▲ | $-271.46M ▼ |
| Q2-2024 | $4.47M | $345.95M | $-230.18M | -5.14K% | $-0.31 | $-222.56M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $4.39B ▼ | $5.06B ▲ | $257.14M ▲ | $4.36B ▲ |
| Q1-2025 | $4.5B ▼ | $5.03B ▼ | $216.7M ▼ | $4.35B ▼ |
| Q4-2024 | $4.89B ▼ | $5.44B ▼ | $249.74M ▼ | $4.69B ▼ |
| Q3-2024 | $5.15B ▼ | $5.79B ▼ | $256.38M ▼ | $5.19B ▲ |
| Q2-2024 | $5.39B | $6.21B | $625.99M | $5.15B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-113.52M ▲ | $-185.66M ▲ | $120.42M ▲ | $62.59M ▲ | $-1.45M ▲ | $-193.51M ▲ |
| Q1-2025 | $-273.91M ▼ | $-204.38M ▼ | $-1.09B ▼ | $-187.77M ▼ | $-1.48B ▼ | $-208.42M ▼ |
| Q4-2024 | $-252.38M ▼ | $-172.56M ▲ | $1.07B ▲ | $-177.15M ▲ | $723.99M ▲ | $-173.38M ▲ |
| Q3-2024 | $118.08M ▲ | $-207.25M ▲ | $454.07M ▲ | $-272.95M ▼ | $-27.2M ▲ | $-209.08M ▲ |
| Q2-2024 | $-279.92M | $-266.81M | $-3.29B | $-109.07M | $-3.66B | $-267.8M |
Revenue by Products
| Product | Q2-2023 | Q2-2024 | Q3-2024 | Q1-2025 |
|---|---|---|---|---|
 Product Revenue Net | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ |
CEO
Matthew Gline
Compensation Summary
(Year 2023)
ETFs Holding This Stock
Summary
Showing Top 3 of 215
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Goldman Sachs
Buy
HC Wainwright & Co.
Buy
Citigroup
Buy
Guggenheim
Buy
Jefferies
Buy
Leerink Partners
Outperform
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
FMR LLC
Shares:60.77M
Value:$1.45B
MORGAN STANLEY
Shares:44.32M
Value:$1.06B
SB INVESTMENT ADVISERS (UK) LTD
Shares:40.32M
Value:$959.9M
Summary
Showing Top 3 of 361